Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

 https://sabcs.onlineeventpro.freeman.com/single-file-viewer/25581217 https://sabcs.onlineeventpro.freeman.com/posters/25581681/A-phase-II-study-to-evaluate-the-efficacy-and-safety-of-Pembrolizumab-plus-Carboplatin-in-BRCA-related-metastatic-breast-cancer-PEMBRACA-trial https://sabcs.onlineeventpro.freeman.com/posters/25582066/Associations-with-response-to-PolyADP-ribose-Polymerase-PARP-inhibitors-in-patients-with-BRCA-mutated-metastatic-breast-cancer-Results-of-a-meta-regression-analysis https://sabcs.onlineeventpro.freeman.com/posters/25582134/Parp-inhibitors-for-treatment-of-brca-positive-metastatic-breast-cancer-a-systematic-review-and-meta-analysis https://sabcs.onlineeventpro.freeman.com/posters/25581843/Efficacy-of-combined-CDK46-inhibitor-and-PARP-inhibitor-in-the-treatment-of-BRCA1-mutant-triple-negative-breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582158/Real-world-clinical-outcomes-of-patients-with-BRCA-mutated-BRCAm-HER2-negative-metastatic-breast-cancer

  https://sabcs.onlineeventpro.freeman.com/posters/25581599/A-prospective-randomized-multicenter-double-blinded-placebo-controlled-phase-III-trial-of-the-HER2neupeptide-GP2--GM-CSF-versus-bacteriostatic-salineWFI-placebo-as-adjuvant-therapy-after-any-trastuzumab-based-therapy-in-HER2-positive-women-with-operable-breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25581541/Tailored-axillary-surgery-with-or-without-axillary-lymph-node-dissection-followed-by-radiotherapy-in-patients-with-clinically-node-positive-breast-cancer-SAKK-2316--IBCSG-57-18--ABCSG-53--GBG-101---TAXIS-a-multicenter-randomized-phase-III-trial https://sabcs.onlineeventpro.freeman.com/single-file-viewer/25582199

https://sabcs.onlineeventpro.freeman.com/live-stream/19758155/ES1-Educational-Session   NOVIDADES NO TRATAMENTO DE PRIMEIRA LINHA E SEGUNDA LINHA , MECANISMOS DE RESISTENCIA E POSSIBILIDADES TERAPEUTICAS DE ASSOCIAÇÕES ANTI-PI3K, INIB. CICLINA KINASE, TUMORES MUTAÇÃO BRCA.

Na duvida postei primeiro o comentário da Julie white ,  sobre Seema Khan , fica Realmente a questão sera que não vale a pena operar pacientes com Doença metastática De Novo, deixarei algumas urls, do Pubmed para discussão : Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018;3(3):CD011276. Published 2018 Mar 15. doi:10.1002/14651858.CD011276.pub2 Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011. JAMA Surg. 2016;151(5):424‐431. doi:10.1001/jamasurg.2015.4539 Lane WO, Thomas SM, Blitzblau RC, et al. Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. Ann Surg. 2019;269(3):537‐544. doi:10.1097/SLA.0000000000002621 Xiong Z, Deng G, Wang J, et al. Could local surgery improve survival in de novo stage IV breast cancer?. BMC

Para os Pacientes com EGFR mutado , após cirurgia , Novo tratamento Standart of care , para câncer de pulmão .  Dados são impressionantes para estadios IB ( DFS 77,93% Hr(0,50 ) )   ,  II ( DFS 82,95% Hr (0,17)   IIIA  (  DFS  79,94 Hr 0,12 ) em dois anos de Follow up .  Importante considerar que foram incluídos pacientes que fizeram quimioterapia até 26 semanas após e sem quimioterapia 10 semanas , redução do risco de morte e recidiva foi de 79% .